CABL001X2101 = A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With CML or Ph+ ALL [Asia, Australia, Europe]

Study title

CABL001X2101 = A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With CML or Ph+ ALL [Asia, Australia, Europe]

Scientific title

A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) (EudraCT 2013-004491-36, ClinicalTrials.gov NCT02081378)

Indication and most important inclusion criteria

Patients 18 years and older with Philadelphia chromosome-positive CML in chronic or accelerated phase who were previously treated with two different tyrosine kinase inhibitors (TKIs) and are relapsed, resistant to or intolerant of TKIs.
Adult patients with cytopathologically confirmed Ph+ ALL who are relapsed or resistant to one prior TKI or intolerant of TKIs.
TKI failure for Ph+ ALL patients is defined as at least the loss of Molecular Response (MR) 4.5 (BCR-ABL ≤ 0.0032%).

Short description of intervention

This first-in-human, open label, dose finding study is conducted to establish a safe and tolerated dose of ABL001 in CML and Ph+ ALL patients who are relapsed or resistant to or are intolerant of TKIs. In these patients, ABL001 may provide a novel therapeutic option.
ABL001 capsules will be administered orally in a dose escalation schedule.

Type of study

Trial after therapy failure or intolerance

Current status

recruiting

Study sponsor

Novartis Pharmaceuticals

Scientific lead / contact

Novartis Pharmaceuticals

Principal investigator

For Germany:
Prof. Dr. Oliver Ottmann
Universitätsklinikum Frankfurt

Additional information

Study description in the US register ClinicalTrials.gov, a service of the U. S. National Institutes of Health 

Study centers / principal investigators

Australia, South Australia
Adelaide, 5000
Novartis Investigative Site

France
Bordeaux, 33076
Novartis Investigative Site

Paris, Cedex 10, 75475
Novartis Investigative Site

Germany
Charité
13353 Berlin

Universitätsklinikum Frankfurt
60590 Frankfurt

Universitätsklinikum Jena
Klinik für Innere Medizin II. Abteilung Hämatologie und Internistische Onkologie
07743 Jena

Italy
Roma, 00161
Novartis Investigative Site

Japan
Kobe-city, Hyogo, 650-0017
Novartis Investigative Site

Korea, Republic of
Seoul, 137-701
Novartis Investigative Site

Netherlands
Amsterdam, 1081 HV
Novartis Investigative Site

Singapore
Singapore, 28006
Novartis Investigative Site

Spain
Madrid, 28006
Novartis Investigative Site

USA
Massachusetts
Dana Farber Cancer Institute
Hematology / Oncology
Boston, 02215

Michigan
University of Michigan Comprehensive Cancer Center SC
Ann Arbor, 48109-0944

New York
Memorial Sloan Kettering Cancer Center
New York, 10065

Oregon
Oregon Health & Science University SC-6
Portland, 97239

Texas
University of Texas
MD Anderson Cancer Center
Houston, 77030-4009

Utah
University of Utah
Huntsman Cancer Institute
Salt Lake City, 84112

 

CLR_15_03 = Safety and anti-leukemic activity of vodobatinib (K0706) for refractory/intolerant CML [Asia, Europe, USA]

Study title

Safety and anti-leukemic activity of vodobatinib (K0706) for treatment of refractory/intolerant CML failing 3 or more prior CML therapies

Scientific title

A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) (EudraCT 2016-001754-18, ClinicalTrials.gov NCT02629692)

Indication and most important inclusion criteria

This study includes male or female patients who:

- are willing and able to give written, and dated, informed consent
- are at least 18 years old
- are willing and able to comply with the scheduled visits
- have an Eastern Co-Operative Group (ECOG) status of 0, 1 or 2
- have adequate organ and immune system function
- have been diagnosed with Ph+ CML-CP, Ph+ CML-AP, Ph+ CML-BP, who are resistant and/or intolerant to ≥ 3 prior TKIs one of which includes ponatinib.

Short description of intervention

K0706 is being developed for patients with heavily pre-treated chronic myeloid leukemia who have limited or no treatment options. It is hoped that the drug will provide patients with advanced disease an opportunity of clinical benefit and improved life expectancy. The Phase 1 dose escalation study is completed and Phase 2 study has been initiated.

This is an open label, Phase 2 study to determine the efficacy and safety of the novel tyrosine kinase inhibitor vodobatinib (K0706).

Type of study

2. Trials after therapy failure or intolerance

Current status

Recruiting

Part A in healthy volunteers: Completed.
Part B: Dose escalation completed, dose expansion study nearing completion (open only in India and Korea)
Part C: Ongoing globally in all countries

Study sponsor

Sun Pharma Advanced Research Company (SPARC) Limited, India

Scientific lead / contact

Geetanjali Chimote, MBBS,PhD, SPARC
geetanjali.chimote@sparcmail.com

Principal investigator

Jorge Cortes, MD
Georgia Cancer Center
Jorge.cortes@augusta.edu

Additional information

Study description in the US register ClinicalTrials.gov, a service of the U. S. National Institutes of Health

Study description in the EU Clinical Trials Register which is hosted by the European Medicines Agency (EMA)

ASH 2019 poster on phase 1 trial of K0706

ESH 2020 conference abstract on vodobatinib in CML patients failing TKI therapies including ponatinib

Study centers / principal investigators

Belgium

UZ Leuven
[Recruiting]
Leuven, Belgium, 3000
Contact: Peter Vandenberghe

ZNA Stuivenberg
[Recruiting]
Antwerpen, Belgium, 2060
Contact: Nikki Granacher

Cliniques Universitaires Saint-Luc
[Recruiting]
Bruxelles, Belgium, 1200
Contact: Violaine Havelange

France

Institut Paoli Calmettes
[Recruiting]
Marseille Cedex 9, Bouches-du-Rhône, France, 13273
Contact: Aude Charbonnier

Centre Hospitalier Lyon Sud
[Recruiting]
Pierre-Bénite, Rhone, France, 69495
Contact: Xavier Thomas

Hôpital Avicenne
[Recruiting]
Bobigny cedex, Seine Saint Denis, France, 93009
Contact: Thorsten Braun

Hopital Claude Huriez - CHRU Lille
[Recruiting]
Lille cedex, Nord, France, 59037
Contact: Valérie Coiteux

CHU de Nantes - Hotel Dieu
[Recruiting]
Nantes cedex 1, Loire Atlantique, France, 44000
Contact: Viviane Dubruille

CHU Rennes - Hopital Pontchaillou
[Recruiting]
Rennes cedex 9, Ille Et Vilaine, France, 35033
Contact: Martine Escoffre-Barbe

Institut Bergonié
[Recruiting]
Bordeaux cedex, Gironde, France, 33076
Contact: Gabriel Etienne

Centre Léon Bérard
[Recruiting]
Lyon Cedex 08, Rhone, France, 69373
Contact: Franck Nicolini

Hôpital Saint-Louis
[Recruiting]
Paris cedex 10, Paris, France, 75475
Contact: Delphine Rea

CHU Poitiers - Hôpital la Milétrie
[Recruiting]
Poitiers, Vienne, France, 86021
Contact: Emilie Cayssials

CHU Amiens - Hopital Sud
[Not yet recruiting]
Salouel, Somme, France, 80480
Contact: Gouin Charbonnier

CHU de Nancy - Hôpital de Brabois Adultes
[Recruiting]
Vandoeuvre-lès-Nancy, Meurthe Et Moselle, France, 54511
Contact: Agnès Guerci-Bresler

CHU Angers - Hôpital Hôtel Dieu
[Recruiting]
Angers, Maine Et Loire, France, 49033
Contact: Mathilde Hunault

CHU de Limoges - Hôpital Dupuytren
[Recruiting]
Limoges cedex, Haute Vienne, France, 87042
Contact: Pascal Turlure

Hungary

Pecsi Tudomanyegyetem
[Recruiting]
Pecs, Hungary, 7624
Contact: Hussain Alizadeh

Semmelweis Egyetem
[Recruiting]
Budapest, Hungary, 1083
Contact: Zsolt Nagy

SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz
[Recruiting]
Nyiregyhaza, Hungary, 4400
Contact: Laszlo Rejto

Debreceni Egyetem
[Recruiting]
Debrecen, Hungary, 4032
Contact: Arpad Illes

India

Prince Aly Khan Hospital
[Recruiting]
Mumbai, Maharashtra, India, 400010
Contact: Tapan Saikia

Chittaranjan National Cancer Institute
[Recruiting]
Kolkata, West Bengal, India, 700026
Contact: Kalyan Mukherjee

Meenakshi Mission Hospital & Research Centre
[Recruiting]
Madurai, Tamilnadu, India, 625107
Contact: Krishna Rathnam

Tata Memorial Hospital
[Recruiting]
Mumbai, Maharashtra, India, 400012
Contact: Navin Khattry

Sahyadri Specialty Hospital
[Recruiting]
Pune, Maharashtra, India, 411004
Contact: Shashikant J Apte

Tata Medical Centre
[Recruiting]
Kolkata, West Bengal, India, 700156
Contact: Vivek S Radhakrishnan


Italy

Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori
[Recruiting]
Meldola, Forli - Cesena, Italy, 47014
Contact: Alessandro Lucchesi

Azienda Socio Sanitaria Territoriale Niguarda (Grande Ospedale Metropolitano
Niguarda)
[Recruiting]
Milano, Italy, 20162
Contact: Ester Pungolino

Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo)
[Recruiting]
Monza, Milano, Italy, 20900
Contact: Carlo Gambacorti Passerini

Ospedale Sant'Eugenio
[Recruiting]
Roma, Italy, 00144
Contact: Elisabetta Abruzzese

Azienda Ospedaliera Universitaria Careggi
[Not yet recruiting]
Firenze, Italy, 50134
Contact: Barbara Scappini

Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La
Sapienza
[Not yet recruiting]
Roma, Italy, 00161
Contact: Martelli

Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
[Recruiting]
Milano, Italy, 20122
Contact: Alessandra Iurlo

Azienda Ospedaliera Universitaria "Policlinico - Vittorio Emanuele" (Presidio
Ferrarotto Alessi)
[Recruiting]

Catania, Italy, 95124
Contact: Fabio Stagno


Romania

Spitalul Clinic Coltea
[Recruiting]
Bucuresti, Romania, 030171
Contact: Gabriela Borsaru

Institutul Oncologic "Prof. Dr. Ion Chiricuta" Cluj-Napoca
[Recruiting]
Cluj-Napoca, Romania, 400124
Contact: Delia Dima

Spitalul Clinic Judetean de Urgenta Targu Mures
[Recruiting]
Târgu Mure#, Romania, 540136
Contact: Ioan Macarie

Spitalul Clinic Colentina
[Recruiting]
Bucuresti, Romania, 020125
Contact: Viola-Maria Popov

Spitalul Clinic Municipal Filantropia Craiova
[Recruiting]
Craiova, Romania, 200143
Contact: Luminita Ocroteala

Singapore

Singapore General Hospital
[Not yet recruiting]
Singapore, Singapore, 169856
Contact: Thuan Heng Charles Chuah


South Korea

The Catholic University of Korea, Seoul St. Mary's Hospital
[Not yet recruiting]
Seoul, Gyeonggi-do, South Korea, 06591
Contact: Dong-Wook Kim


Spain

Hospital Universitario 12 de Octubre
[Recruiting]
Madrid, Spain, 28041
Contact: Rosa Ayala Diaz

Hospital Universitario La Paz
[Recruiting]
Madrid, Spain, 28046
Contact: Raquel de Paz Arias

Hospital Universitario Ramon y Cajal
[Recruiting]
Madrid, Spain, 28034
Contact: Valentín García Gutiérrez

Hospital Universitario Virgen del Rocio
[Recruiting]
Sevilla, Spain, 41013
Contact: Isabel Montero Cuadrado,

Hospital Universitari Vall d'Hebron
[Recruiting]
Barcelona, Spain, 08035
Contact: Guillermo Ortí

Hospital Universitario de Salamanca
[Recruiting]
Salamanca, Spain, 37007
Contact: Fermin Sanchez-Guijo

ICO Badalona - Hospital Universitari Germans Trias i Pujol
[Recruiting]
Badalona, Barcelona, Spain, 08916
Contact: Blanca Xicoy

ICO Girona - Hospital Universitari de Girona Dr Josep Trueta
[Recruiting]
Girona, Spain, 17007
Contact: Anna Angona Figueras

Hospital Clinico Universitario Virgen de la Victoria
[Not yet recruiting]
Málaga, Spain, 29010
Contact: Regina Garcia

Hospital Universitario Virgen Macarena
[Recruiting]
Sevilla, Spain, 41009
Contact: Juan Antonio Vera Goñi


United Kingdom

King's College Hospital
[Recruiting]
London, Greater London, United Kingdom, SE5 9NU
Contact: de Lavallade Hugues

Hammersmith Hospital
[Recruiting]
London, Greater London, United Kingdom, W120HS
Contact: Jane Apperley

United States

United States, California
University of Southern California
[Recruiting]
Los Angeles, California, United States, 90033
Contact: George Yaghmour

United States, Texas
MD Anderson Cancer Center
[Recruiting]
Houston, Texas, United States, 77030
Contact: Yesid Alvarado-Valero

United States, New York
New York Medical College
[Not yet recruiting]
Valhalla, New York, United States, 10595
Contact: Karen Seiter

United States, New York
Memorial Sloan Kettering Cancer Center - MAIN
[Active, not recruiting]
New York, New York, United States, 10065
Contact: Mauro Michael

United States, California
The Oncology Institute of Hope and Innovation, Innovative Clinical Research
Institute
[Recruiting]
Downey, California, United States, 90241
Contact: Richy Agajanian

United States, Utah
Huntsman Cancer Institute University of Utah
[Recruiting]
Salt Lake City, Utah, United States, 84112
Contact: Michael Deininger

United States, North Carolina
East Carolina University
[Not yet recruiting]
Greenville, North Carolina, United States, 27858
Contact: Darla Liles

United States, Indiana
IU Simon Cancer Center
[Recruiting]
Indianapolis, Indiana, United States, 46202
Contact: Hamid Sayar

United States, Georgia
Board of Regents of the University System of Georgia
[Recruiting]
Augusta, Georgia, United States, 30912
Contact: Jorge Cortes

United States, Texas
Baylor University Medical Center
[Recruiting]
Dallas, Texas, United States, 75226
Contact: Andrew Whiteley

United States, California
UCLA Hematologic Malignancy Program
[Not yet recruiting]
Los Angeles, California, United States, 90024
Contact: Wanxing Chai-Ho

United States, New Jersey
Hackensack University Medical Center
[Not yet recruiting]
Hackensack, New Jersey, United States, 07601
Contact: James McCloskey

 

PONS = Ponatinib in Second Line [Germany]

Study title

PONS Study = Ponatinib for Treatment of Patients with CP-CML after Treatment with Other TKI has Failed

Scientific title

PONS Phase 2 Clinical Trial with Ponatinib 30mg as a Second Line Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to First Line Tyrosine Kinase Inhibitor Treatment
(EudraCT number: 2016-000618-30 / ClinicalTrials.gov no NCT03807479)

Indication and most important inclusion criteria

Adult patients (age ≥ 18) diagnosed with Ph-positive (by cytogenetics) or BCR-ABL-positive (by PCR) chronic myeloid leukemia (CML) in chronic phase.

Patients should have demonstrated to have
- a failure of a prior first line TKI treatment with either imatinib, dasatinib or nilotinib, defined as per European LeukemiaNet (ELN) recommendations,
- or intolerance to prior TKI treatment defined as grade 3 or 4 toxicity, or persistent grade 2 toxicity despite optimal management including dose adjustment, or in a patient where dose reductions are considered to be not in the patient's best interest to obtain an adequate response. Intolerant patients should not have achieved or have lost major cytogenetic molecular response at the time of enrollment.

Patients should also have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, as well as adequate function of liver, kidney and pancreas. Patients should have fully recovered from the acute effects of prior cancer therapy.

Pregnant patients cannot be included.

Additional criteria may apply.

Short description of intervention

This is a non-randomized, open label study evaluating the safety and efficacy of second line ponatinib therapy in patients suffering from Chronic Myeloid Leukemia in Chronic Phase and who are resistant or intolerant to earlier treatment with another Tyrosine Kinase Inhibitor (TKI). Ponatinib will be given at a dose of 30mg. The dose may be reduced further to 15mg. The study is being performed in Germany.

Type of study

2. Second line trials after therapy failure

Current status

Recruiting

Study sponsor

GWT-TUD GmbH
Incyte Biosciences International Sàrl

Scientific lead / contact

J. Bernds
GWT-TUD GmbH

Principal investigator

Prof. Dr. med. Philipp le Coutre
Charité - Universitätsmedizin Berlin
Department of Hematology, Oncology and Tumor Immunology
10117 Berlin, Germany

Additional information

Study description in the EU Clinical Trials Register which is hosted by the European Medicines Agency (EMA)

Study centers / principal investigators

Germany

Aachen
Universitätsklinikum RWTH Aachen
Medizinische Klinik IV
Dr. med. Martina Crysandt

Berlin
Charité - Universitätsmedizin Berlin
Campus Virchow Klinikum
Prof. Dr. med. Philipp le Coutre

Essen
Universitätsklinikum Essen gGmbH
Dr. med. Joachim Göthert

Greifswald
Universitätsmedizin Greifswald
Prof. Dr. med. Christian Andreas Schmidt

Hamburg
Asklepios Klinik St. Georg

Mannheim
III. Med. Klinik
Medizinische Fakultät Mannheim der Universität Heidelberg
Prof. Dr. med. Susanne Saußele

Marburg
Universitätsklinikum Gießen und Marburg GmbH
Prof. Dr. med. Andreas Burchert

Minden
UKRUB Universitätsklinik der Ruhr-Universität Bochum

Ulm
Universitätsklinikum Ulm

 

RT51KRI03 = Radotinib in Chronic Phase Chronic Myeloid Leukemia [Republic of Korea, Russia, Turkey, Ukraine]

Study title

Efficacy and Safety of Radotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase With Failure or Intolerance to Previous TKIs

Scientific title

A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs (ClinicalTrials.gov no. NCT03459534)

Indication and most important inclusion criteria

Male or female patients 18 years or older with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP). Patients can be considered for inclusion in the study if they were previously treated with a tyrosine kinase inhibitor (TKI) including imatinib but did not respond to or tolerate treatment. Kidney and liver function must be adequate

Other criteria may apply.

Short description of intervention

This study is conducted to evaluate the efficacy and safety of radotinib 400 mg twice daily for 12 months in patients with Ph+ CML in chronic phase who did not respond or were intolerant to previous TKI therapy.

Type of study

Trial after therapy failure or intolerance

Current status

Recruiting

Study sponsor

Il-Yang Pharm. Co., Ltd.

Scientific lead / contact

Hye Lin Park, Il-Yang Pharm. Co., Ltd.
Jeong Hye Kim, Il-Yang Pharm. Co., Ltd.

Principal investigator

Dong-Wook Kim, MD
The Catholic University of Korea's St. Mary's Hospital

Additional information

Study description in the US register ClinicalTrials.gov, a service of the U. S. National Institutes of Health

Study centers / principal investigators

Korea, Republic of

Seoul
The Catholic University of Korea, Seoul
St. Mary's Hospital
Principal Investigator: Dong-Wook Kim
Seoul, 0659

Russia

Territorial State Budgetary Institution of Healthcare
Territorial Clinical Hospital
Barnaul, 656024
(not yet recruiting)

Federal State Budgetary Institution of Science
Kirov Scientific and Research Institute of Hematology and Blood Transfusion of the Federal Medical and Biological Agency
Kirov, 610027

Federal State Budgetary Institution
Moscow, 125167
(not yet recruiting)

Hematology Centre based on City Clin. Hosp. n.a. S.P. Botkin
Moscow, 300186883

Federal State Budgetary Institution
Saint-Petersburg, 191024

Federal State Budgetary Institution
Saint-Petersburg, 197341

Turkey

Ankara
Ankara University Medical Faculty
Principal Investigator: Muhit Ozcan

Ankara
Gazi University Medical Faculty
Principal Investigator: Munci Yagci

Istanbul
Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty
Principal Investigator: Ahmet Eskazan

Izmir
Ege University Medical Faculty
Principal Investigator: Guray Saydam

Mersin
Mersin University Medical Faculty

Samsun
Ondokuz Mayis Univ. Med. Fac.
Principal Investigator: Mehmet Turgut


Ukraine

Cherkassy
CI Cherkasy Regional Oncological Dispensary of CRC
Principal Investigator: Halyna Pylypenko

Chernihiv
CTPI Chernihiv Regional Oncological Dispensary
Principal Investigator: Alla Nahorna

Dnipro
CI Dnipropetrovsk CMCH #4 OF Dnipropetrovsk RC
Principal Investigator: Anna Usenko

Kyiv
Institute of CR of SI NSC of Radiation Medicine of NAMSU H&T Unit
Principal Investigator: Iryna Dyagil

Lviv
SI Institute of Blood Pathology and Transfusion Medicine of AMSU
Principal Investigator: Zvenyslava Maslyak

HQP1351CU101 = Study of HQP1351 in subjects with refractory chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia [USA]

Study title

HQP1351CU101 = Study of HQP1351 in subjects with refractory chronic myeloid leukemia

Scientific title

A Phase Ib Study of the Pharmacokinetics, Safety and Efficacy of Orally Administered HQP1351 in Subjects With Refractory Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL) (ClinicalTrials.gov NCT04260022)

Indication and most important inclusion criteria

This study includes male or female patients 18 years and older with CML in chronic phase (CP) or accelerated phase (AP) or blast phase (BP) or with Ph+ ALL, with or without T315I mutation.

Eligible patients will be previously treated with and developed resistance or intolerance to at least three tyrosine kinase inhibitors (TKIs), including ponatinib, imatinib, dasatinib, nilotinib, or bosutinib. For patients with a T315I mutation, resistance or intolerance to ponatinib alone is acceptable.

To be considered for inclusion, patients must have adequate end-organ function, and an Eastern Co-Operative Oncology Group (ECOG) status of 0, 1 or 2.

Additional criteria may apply.

Short description of intervention

This is a phase 1b study to evaluate the pharmacokinetics of HQP1351 and to determine the recommended dose for phase 2 in subjects with CML CP, AP or BP or with Ph+ ALL, who have developed resistance or intolerance to at least three prior TKIs. The preliminary efficacy and safety of HQP1351 in these patients will be evaluated as well.

In this study, patients will receive HQP1351 at a dose of either 30 mg, 40 mg or 50 mg every other day for 28 days.

Type of study

Trial after therapy failure or intolerance

Current status

Recruiting

Study sponsor

Ascentage Pharma Group Inc.

Scientific lead / contact

Yifan Zhai, MD, PhD
Ascentage Pharma Group Inc.

Principal investigator

Study chair: Yifan Zhai, MD, PhD
Ascentage Pharma Group Inc.

Additional information

Study description in the US register ClinicalTrials.gov, a service of the U. S. National Institutes of Health 

Study centers / principal investigators

United States

Arkansas

Highlands Oncology
Rogers, Arkansas, 72758
Principal Investigator: Thad Beck, MD

Georgia

Winship Cancer Institute, Emory University
Atlanta, Georgia, 30322
Principal Investigator: Rebecca Klisovic, MD

Ohio

Cleveland Clinic
Cleveland, Ohio, 44195
Principal Investigator: Sudipto Mukherjee, MD

Texas

University of Texas MD Anderson Cancer Center
Houston, Texas, 77030
Contact: Elias Jabbour, MD

Washington

Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109
Principal Investigator: Vivian Oehler, MD


Please donate!

Please donate!

LogIn

EU e-Privacy Directive